CytoDyn, Inc. (CYDY)
0.20
0.00 (0.00%)
USD |
OTCM |
Oct 14, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 274.70M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -28.06% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -0.2781 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 98.76% |
Profile
| CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development and potential commercialization of its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its current clinical development activities focus on solid-tumor oncology, including colorectal cancer and metastatic triple-negative breast cancer, and the development of a long-acting version of leronlimab. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA. |
| URL | http://www.cytodyn.com |
| Investor Relations URL | N/A |
| HQ State/Province | Washington |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Oct. 15, 2026 (est.) |
| Last Earnings Release | Oct. 15, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development and potential commercialization of its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its current clinical development activities focus on solid-tumor oncology, including colorectal cancer and metastatic triple-negative breast cancer, and the development of a long-acting version of leronlimab. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA. |
| URL | http://www.cytodyn.com |
| Investor Relations URL | N/A |
| HQ State/Province | Washington |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Oct. 15, 2026 (est.) |
| Last Earnings Release | Oct. 15, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |